---
document_datetime: 2025-12-02 05:37:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/enflonsia.html
document_name: enflonsia.html
version: success
processing_time: 0.0407756
conversion_datetime: 2025-12-28 00:40:52.776533
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Enflonsia

[RSS](/en/individual-human-medicine.xml/266956)

##### Opinion

EMA has issued an opinion on this medicine

clesrovimab Medicine Human Opinion

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [News on Enflonsia](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Update from 14 November 2025: The applicant has informed the Agency about a revised dataset that will be submitted. As a result, the Commission Decision process is currently put on hold while we await this information from the applicant.

On 18 September 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Enflonsia, intended for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season. The applicant for this medicinal product is Merck Sharp &amp; Dohme B.V.

Enflonsia will be available as a 105 mg solution for injection in pre-filled syringes. The active substance of Enflonsia is clesrovimab, an antiviral monoclonal antibody (ATC code: J06BD10). Clesrovimab is a fully human immunoglobulin G1 kappa (IgG1Îº) neutralising monoclonal antibody with a triple amino acid substitution in the Fc region which increases binding to the neonatal Fc receptor leading to an extended serum half-life. Clesrovimab provides passive immunity by targeting the RSV outer membrane fusion protein to prevent viral entry into cells.

The benefit of Enflonsia is the prevention of RSV lower respiratory tract disease in neonates and infants during their first RSV season. The most common side effects include injection-site pain, injection-site erythema, injection-site swelling and rash.

The full indication is:

Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.

Enflonsia should be used in accordance with official recommendations.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.

CHMP summary of positive opinion for Enflonsia

Adopted

Reference Number: EMA/CHMP/274513/2025

English (EN) (157.37 KB - PDF)

**First published:** 19/09/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-enflonsia_en.pdf)

## Product details

Name of medicine Enflonsia Active substance clesrovimab International non-proprietary name (INN) or common name clesrovimab Therapeutic area (MeSH) Respiratory Syncytial Virus Vaccines Anatomical therapeutic chemical (ATC) code J06BD10 EMA product number EMEA/H/C/006497 Marketing authorisation applicant Merck Sharp  Dohme Limited Opinion adopted 18/09/2025 Opinion status Positive

#### News on Enflonsia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-september-2025) 19/09/2025

**This page was last updated on** 14/11/2025

## Share this page

[Back to top](#main-content)